Pembrolizumab for the treatment of Hodgkin Lymphoma.
Samer A Al HadidiHun Ju LeePublished in: Expert opinion on biological therapy (2020)
Immune CPIs that block PD-1/PD-L1 and PD-L2 interaction are an effective strategy in R/R cHL. Pembrolizumab demonstrated safety and efficacy in the treatment of R/R cHL. The optimal utilization of pembrolizumab in frontline therapy is under investigation.